Agenus Inc. reported $133M of revenue over the trailing twelve months, +30% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $133M (to Q2 2026). Net income: $92M, trailing twelve months to Q2 2026. Free cash flow: −$99M, trailing twelve months to Q2 2026. Operating margin: 26%, trailing twelve months to Q2 2026.

AGENAgenus Inc.

Healthcare

$3.03-39% 1Y

$3.03

$2.7752 weeks$9.93

AGEN as reported

Agenus Inc. reported $133M of revenue over the trailing twelve months, +30% on the year before. 10 reported series are charted on this page, each one as filed.

$133M

Revenue, trailing twelve months · to Q2 2026 · +30% against the twelve months before

Net income: $92M
Net income · −154% year on year · trailing twelve months to Q2 2026
Free cash flow: −$99M
Free cash flow · −23% year on year · trailing twelve months to Q2 2026
Operating margin: 26%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for AGEN, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$133M	+30%	Q2 2026
Net income	$92M	−154%	Q2 2026
EPS	$2.58	−137%	Q2 2026
Gross margin	99%	n/a	Q2 2026
Operating margin	26%	n/a	Q2 2026
Net margin	74%	n/a	Q2 2026
ROE	−15%	n/a	Q2 2026
ROA	17%	n/a	Q2 2026
ROIC	2.1%	n/a	Q2 2026
Free cash flow	−$99M	−23%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.